Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Frederick L. Locke(Moffitt Cancer Center), Saurabh Dahiya(Stanford University), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Amanda F. Cashen(Washington University in St. Louis), Khoan Vu(University of California, San Francisco), Olalekan O. Oluwole(Vanderbilt University), Jay Y. Spiegel(Stanford Medicine), Alison R. Sehgal(UPMC Hillman Cancer Center), Abhinav Deol(Wayne State University), Joseph P. McGuirk(University of Kansas Medical Center), Lei Feng(Ministry of Public Security of the People's Republic of China), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Charalambos Andreadis(University of California, San Francisco), N. Nora Bennani(Mayo Clinic in Arizona), Lazaros J. Lekakis(University of Miami Hospital), Patrick M. Reagan(University of Rochester), Aaron P. Rapoport(University of Maryland, Baltimore), Julie M. Vose(University of Nebraska Medical Center), David B. Miklos(Stanford University), Julio C. Chávez(Moffitt Cancer Center), Armin Ghobadi(Washington University in St. Louis), Matthew A. Lunning(University of Nebraska Medical Center), André Goy(Hackensack University Medical Center), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Michael D. Jain(Moffitt Cancer Center), Yi Lin, Brian T. Hill(Cleveland Clinic)
Cited by 782
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
|New England Journal of Medicine|2004|1.4k